Total Payments
$24,536
2024 Payments
$21.37
Companies
8
Transactions
15
Medicare Patients
348
Medicare Billing
$45,399
Payment Breakdown by Category
Research$14,108 (57.5%)
Consulting$8,020 (32.7%)
Other$2,332 (9.5%)
Food & Beverage$76.16 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14,108 | 5 | 57.5% |
| Consulting Fee | $8,020 | 3 | 32.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,332 | 3 | 9.5% |
| Food and Beverage | $76.16 | 4 | 0.3% |
Payments by Type
Research
$14,108
5 transactions
General
$10,428
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $7,669 | 3 | $0 (2020) |
| Amgen Inc. | $7,214 | 1 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $4,475 | 3 | $0 (2021) |
| Gilead Sciences, Inc. | $2,770 | 1 | $0 (2020) |
| F. Hoffmann-La Roche AG | $2,332 | 3 | $0 (2018) |
| Agios Pharmaceuticals, Inc. | $31.80 | 2 | $0 (2018) |
| Blue Earth Diagnostics Limited | $22.99 | 1 | $0 (2021) |
| Telix Pharmaceuticals | $21.37 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21.37 | 1 | Telix Pharmaceuticals ($21.37) |
| 2021 | $3,023 | 2 | Novartis Pharmaceuticals Corporation ($3,000) |
| 2020 | $5,020 | 2 | Gilead Sciences, Inc. ($2,770) |
| 2019 | $4,010 | 1 | Celgene Corporation ($4,010) |
| 2018 | $9,888 | 6 | Amgen Inc. ($7,214) |
| 2017 | $2,574 | 3 | F. Hoffmann-La Roche AG ($1,699) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/15/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 11/12/2021 | Blue Earth Diagnostics Limited | Axumin (Drug) | Food and Beverage | In-kind items and services | $22.99 | General |
| Category: Diagnostic Imaging | ||||||
| 02/28/2021 | Novartis Pharmaceuticals Corporation | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 10/07/2020 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,770.00 | General |
| 09/23/2020 | Celgene Corporation | ONUREG (Drug) | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| Category: Oncology | ||||||
| 05/08/2019 | Celgene Corporation | Luspatercept (Drug) | — | In-kind items and services | $4,010.00 | Research |
| Study: A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) (ACE-536-MDS-001) | ||||||
| 12/31/2018 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $633.32 | General |
| Category: BioOncology | ||||||
| 12/18/2018 | Amgen Inc. | Aranesp (Biological) | — | In-kind items and services | $7,214.29 | Research |
| Study: The Epidemiology; Costs and Treatments associated with Low and Intermediate-1 Myelodysplastic Syndr • Category: Nephrology | ||||||
| 12/02/2018 | Agios Pharmaceuticals, Inc. | TIBSOVO (Drug) | Food and Beverage | Cash or cash equivalent | $18.16 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2018 | Agios Pharmaceuticals, Inc. | TIBSOVO (Drug) | Food and Beverage | Cash or cash equivalent | $13.64 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | EXJADE (Drug) | — | Cash or cash equivalent | $600.00 | Research |
| Study: A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES LOW INT1 RISK AND TRANSFUSIONAL IRON OVERLOAD TELESTO • Category: HEMATOLOGY | ||||||
| 08/01/2018 | Celgene Corporation | Luspatercept (Drug) | — | In-kind items and services | $1,409.00 | Research |
| Study: ACE-536-MDS-001 - A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) | ||||||
| 06/30/2017 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $889.09 | General |
| Category: BioOncology | ||||||
| 04/29/2017 | NOVARTIS PHARMACEUTICALS CORPORATION | EXJADE (Drug) | — | Cash or cash equivalent | $875.00 | Research |
| Study: A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES LOW INT1 RISK AND TRANSFUSIONAL IRON OVERLOAD TELESTO • Category: HEMATOLOGY | ||||||
| 03/31/2017 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $809.43 | General |
| Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| The Epidemiology; Costs and Treatments associated with Low and Intermediate-1 Myelodysplastic Syndr | Amgen Inc. | $7,214 | 1 |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) (ACE-536-MDS-001) | Celgene Corporation | $4,010 | 1 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED CLINICAL TRIAL OF DEFERASIROX IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES LOW INT1 RISK AND TRANSFUSIONAL IRON OVERLOAD TELESTO | NOVARTIS PHARMACEUTICALS CORPORATION | $1,475 | 2 |
| ACE-536-MDS-001 - A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) | Celgene Corporation | $1,409 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 118 | 139 | $92,055 | $13,751 |
| 2022 | 3 | 83 | 127 | $94,427 | $12,685 |
| 2021 | 4 | 83 | 116 | $83,219 | $11,733 |
| 2020 | 3 | 64 | 85 | $37,164 | $7,230 |
Total Patients
348
Total Services
467
Medicare Billing
$45,399
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 36 | 36 | $34,828 | $5,794 | 16.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 31 | 45 | $31,018 | $3,877 | 12.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2023 | 26 | 27 | $9,693 | $2,432 | 25.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 25 | 31 | $16,516 | $1,647 | 10.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 30 | 68 | $47,216 | $6,016 | 12.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 34 | 34 | $34,136 | $5,502 | 16.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 19 | 25 | $13,075 | $1,166 | 8.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 34 | 62 | $42,344 | $5,727 | 13.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 20 | 20 | $19,330 | $3,274 | 16.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 11 | 11 | $9,966 | $1,389 | 13.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 18 | 23 | $11,579 | $1,343 | 11.6% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 23 | 23 | $13,819 | $3,552 | 25.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 26 | 39 | $15,683 | $2,725 | 17.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 15 | 23 | $7,662 | $952.64 | 12.4% |
About Dr. Peter Greenberg, M.D
Dr. Peter Greenberg, M.D is a Internal Medicine healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1912033978.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Greenberg, M.D has received a total of $24,536 in payments from pharmaceutical and medical device companies, with $21.37 received in 2024. These payments were reported across 15 transactions from 8 companies. The most common payment nature is "" ($14,108).
As a Medicare-enrolled provider, Greenberg has provided services to 348 Medicare beneficiaries, totaling 467 services with total Medicare billing of $45,399. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Hematology
- Location Stanford, CA
- Active Since 02/26/2007
- Last Updated 04/26/2024
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1912033978
Products in Payments
- Aranesp (Biological) $7,214
- Luspatercept (Drug) $5,419
- TECENTRIQ (Biological) $2,332
- ONUREG (Drug) $2,250
- EXJADE (Drug) $1,475
- TIBSOVO (Drug) $31.80
- Axumin (Drug) $22.99
- ILLUCCIX (Drug) $21.37
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Stanford
Dr. Christian Eversull, M.d, M.D
Internal Medicine — Payments: $2.9M
Internal Medicine $2.9M
Glenn Chertow, Md, MD
Internal Medicine — Payments: $1.9M
Internal Medicine $1.9M
Rahul Sharma, Md, MD
Internal Medicine — Payments: $1.0M
Internal Medicine $1.0M
Deepu Madduri, Md, MD
Internal Medicine — Payments: $749,916
Internal Medicine $749,916
Mark Pegram, M.d, M.D
Internal Medicine — Payments: $542,122
Internal Medicine $542,122
Richard Lafayette, M.d, M.D
Internal Medicine — Payments: $499,103
Internal Medicine $499,103